Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.
作者信息
Haberman Rebecca, Axelrad Jordan, Chen Alan, Castillo Rochelle, Yan Di, Izmirly Peter, Neimann Andrea, Adhikari Samrachana, Hudesman David, Scher Jose U
机构信息
New York University Langone Health, New York, NY.
New York University Grossman School of Medicine, New York, NY.
出版信息
N Engl J Med. 2020 Jul 2;383(1):85-88. doi: 10.1056/NEJMc2009567. Epub 2020 Apr 29.
Abstract
摘要
相似文献
1
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.免疫介导性炎症疾病中的新冠病毒病——来自纽约的病例系列
N Engl J Med. 2020 Jul 2;383(1):85-88. doi: 10.1056/NEJMc2009567. Epub 2020 Apr 29.
2
Biologics, spondylitis and COVID-19.生物制剂、脊柱炎与新型冠状病毒肺炎
Ann Rheum Dis. 2020 Dec;79(12):1663-1665. doi: 10.1136/annrheumdis-2020-217941. Epub 2020 Jun 10.
3
National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.德国炎症性风湿病（IRD）患者感染 SARS-CoV-2 的国家登记处（ReCoVery）：了解 IRD 患者 SARS-CoV-2 感染临床病程的快速可靠知识的宝贵手段。
RMD Open. 2020 Sep;6(2). doi: 10.1136/rmdopen-2020-001332.
4
Biologics in systemic autoimmune diseases during COVID-19 pandemic.新冠疫情期间系统性自身免疫性疾病中的生物制剂
Clin Rheumatol. 2020 Dec;39(12):3529-3531. doi: 10.1007/s10067-020-05439-z. Epub 2020 Oct 4.
5
Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.接受生物和合成靶向治疗的风湿性疾病患者中COVID-19的临床特征和结局
Ann Rheum Dis. 2020 Jul;79(7):988-990. doi: 10.1136/annrheumdis-2020-217948. Epub 2020 Jun 5.
6
Should patients stop their biologic treatment during the COVID-19 pandemic.在新冠疫情期间，患者是否应该停止生物制剂治疗？
J Dermatolog Treat. 2020 Jun;31(4):317-318. doi: 10.1080/09546634.2020.1742438. Epub 2020 Mar 19.
7
How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion.如何在 COVID-19 时代处理自身免疫性风湿和炎症性肠病患者：专家意见。
Autoimmun Rev. 2020 Jul;19(7):102574. doi: 10.1016/j.autrev.2020.102574. Epub 2020 May 5.
8
Thoughts on COVID-19 and autoimmune diseases.关于 COVID-19 和自身免疫性疾病的思考。
Lupus Sci Med. 2020 Apr 3;7(1):e000396. doi: 10.1136/lupus-2020-000396. eCollection 2020.
9
Should biologics for psoriasis be interrupted in the era of COVID-19?在新冠疫情时代，银屑病生物制剂是否应中断使用？
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
10
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.风湿性疾病患者因 COVID-19 住院的相关特征：来自 COVID-19 全球风湿病联盟医生报告登记处的数据。
Ann Rheum Dis. 2020 Jul;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29.
引用本文的文献
1
[Guillain-Barré syndrome as an autoimmune neurological manifestation associated with COVID-19: A review of the literature].[吉兰-巴雷综合征作为与新型冠状病毒肺炎相关的自身免疫性神经表现：文献综述]
Rev Colomb Reumatol. 2022 Jun;29:S48-S55. doi: 10.1016/j.rcreu.2021.01.004. Epub 2021 Feb 27.
2
The clinical risk and post-COVID-19 sequelae in patients with myasthenia gravis: a retrospective observational study.重症肌无力患者的临床风险及新冠病毒感染后后遗症：一项回顾性观察研究
Front Neurol. 2025 Apr 2;16:1513649. doi: 10.3389/fneur.2025.1513649. eCollection 2025.
3
Cushing's syndrome and COVID-19.库欣综合征与新型冠状病毒肺炎
Pituitary. 2024 Dec;27(6):945-954. doi: 10.1007/s11102-024-01466-0. Epub 2024 Nov 14.
4
Two Decades Rituximab Therapy in Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis.利妥昔单抗治疗抗中性粒细胞胞浆抗体相关性血管炎二十年
Curr Drug Targets. 2025;26(2):73-87. doi: 10.2174/0113894501323529240910015912.
5
Long COVID Definition, Symptoms, Risk Factors, Epidemiology and Autoimmunity: A Narrative Review.长新冠的定义、症状、风险因素、流行病学及自身免疫：一篇叙述性综述
Am J Med Open. 2024 Feb 14;11:100068. doi: 10.1016/j.ajmo.2024.100068. eCollection 2024 Jun.
6
Aberrant Immune Features after Recovery from COVID-19 in Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases.系统性红斑狼疮及其他自身免疫性疾病患者新冠康复后的异常免疫特征
Biomedicines. 2023 Oct 17;11(10):2807. doi: 10.3390/biomedicines11102807.
7
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase.新冠疫情及疫苗接种运动对大流行头三年中1755例系统性硬化症患者的影响。在下一疫情阶段，免疫反应受损者、正在接受免疫调节治疗者以及患有疾病相关肺部病变者面临的潜在风险。
J Transl Autoimmun. 2023 Oct 9;7:100212. doi: 10.1016/j.jtauto.2023.100212. eCollection 2023 Dec.
8
The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness.皮肤科疾病免疫调节治疗对感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）风险及与冠状病毒病（COVID-19）相关结局的影响
Curr Dermatol Rep. 2023;12(2):45-55. doi: 10.1007/s13671-023-00385-w. Epub 2023 Apr 3.
9
Intestinal Damage, Inflammation and Microbiota Alteration during COVID-19 Infection.新冠病毒感染期间的肠道损伤、炎症及微生物群改变
Biomedicines. 2023 Mar 27;11(4):1014. doi: 10.3390/biomedicines11041014.
10
Outcome of SARS-CoV2 infection in hematopoietic stem cell transplant recipients for autoimmune diseases.SARS-CoV2 感染在接受造血干细胞移植治疗自身免疫性疾病的患者中的结局。
J Autoimmun. 2023 Apr;136:103024. doi: 10.1016/j.jaut.2023.103024. Epub 2023 Mar 2.
本文引用的文献
1
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
2
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
3
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
Zotero 插件